Stifel raised the firm’s price target on Dyne Therapeutics (DYN) to $39 from $36 and keeps a Buy rating on the shares. The firm “refreshed diligence” on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics Announces Upsized Public Offering
- Amazon initiated, GE Vernova upgraded: Wall Street’s top analyst calls
- Oppenheimer upgrades Dyne Therapeutics to Outperform, raises target to $40
- Dyne Therapeutics upgraded to Outperform from Perform at Oppenheimer
- Dyne Therapeutics 18.98M share Secondary priced at $18.44